GCTK (GlucoTrack) Moat Score: 2/10 (As of Jul. 01, 2026)


GCTK GlucoTrack Inc GCTK
19 GF Score
Price $0.34
! 2 Warning Signs
View Full Analysis

What is GlucoTrack Moat Score?

GlucoTrack GCTK +9.13% 19 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates GCTK with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 846 Medical Devices & Instruments companies, GlucoTrack ranks better than 68.2% on this metric.

GlucoTrack has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

GlucoTrack has No Moat: GlucoTrack Inc has very weak competitive advantages with limited market share and no significant intellectual property or brand strength. The company operates in a highly competitive medical device industry with low barriers to entry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GlucoTrack might have No Moat - Very weak/transient advantages.

GlucoTrack  (NAS:GCTK) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GlucoTrack Moat Score Related Terms

GCTK vs YBGJ, RSCF, ECIA: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, GlucoTrack's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlucoTrack Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Moat Score distribution charts can be found below:

* The bar in red indicates where GlucoTrack's Moat Score falls into.


GCTK
19GF Score
GlucoTrack Inc GCTK
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
GlucoTrack (GCTK) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, GlucoTrack ranks #269 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 31.8%.
Is GlucoTrack's Moat Score too high?
GlucoTrack's current Moat Score is 2. Based on the distribution chart, GlucoTrack ranks #269 out of 846 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, GlucoTrack has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GlucoTrack's Moat Score compare to YBGJ and RSCF?
According to the Medical Devices & Instruments industry distribution chart, GlucoTrack ranks #269 out of 846 companies for Moat Score. This puts GlucoTrack in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. GlucoTrack's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlucoTrack stock overvalued right now?
GlucoTrack (GCTK) has a current Moat Score of 2. The current Moat Score is 2. GlucoTrack's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For GlucoTrack (GCTK), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlucoTrack Business Description

Address 301 Route 17 North, Suite 800, Rutherford, NJ, USA, 07070
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
19GF Score

Get the complete analysis for GCTK

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price